Pedersen O D, Jensen H K
Svendborg Sygehus, gynaekologisk-obstetrisk afdeling.
Ugeskr Laeger. 1990 Sep 3;152(36):2561-4.
The effect transcutaneous oestradiol for four months supplemented by medroxyprogesterone (Perlutex) from the 12th to 26th day of every month was assessed in an open uncontrolled prospective investigation in 34 women with menopausal symptoms and follicle stimulating hormone greater than 40 international units and luteinizing hormone greater than 25 international units. A marked effect was found on sweating and hot flushes and other menopausal complaints as expressed by Kupperman's menopausal index. Serum oestradiol increased during the first two months to follicular phase values and this was followed by an unexplained decrease after the fourth month which did not, however, result in aggravation of the symptoms. No alterations were found in steroid-hormone-binding globulin, lipids and body weight. Whether the patients placed the plasters in the hip or abdominal regions was found to be of no significance. Seventeen patients had no side effects of the treatment. Nine patients had transient skin symptoms which disappeared spontaneously. Five patients had mastalgia which disappeared after reduction of the Perlutex dose. One patient developed metrorrhagia. A total of three patients abandoned the treatment: one on account of skin symptoms, one on account of high blood pressure and a third on account of psychiatric symptoms which were unrelated to the treatment. A total of 28 patients wanted to continue treatment after the fourth month.
在一项开放、非对照的前瞻性研究中，对34名有更年期症状且促卵泡激素大于40国际单位、促黄体生成素大于25国际单位的女性，评估了连续四个月经皮补充雌二醇，并在每月第12至26天加用甲羟孕酮（Perlutex）的效果。结果发现，对于出汗、潮热及库珀曼更年期指数所表示的其他更年期不适症状有显著效果。血清雌二醇在头两个月升至卵泡期水平，随后在第四个月出现不明原因下降，但症状并未加重。类固醇激素结合球蛋白、血脂及体重未发现改变。发现患者将贴剂贴于髋部或腹部区域并无影响。17名患者治疗无副作用。9名患者有短暂皮肤症状，后自行消失。5名患者有乳房疼痛，在减少Perlutex剂量后消失。1名患者出现子宫出血。共有3名患者放弃治疗：1名因皮肤症状，1名因高血压，第3名因与治疗无关的精神症状。共有28名患者在第四个月后希望继续治疗。
